Picard Medical Announces Milestone Survivability With SynCardia Total Artificial Heart Support

Fifty-three months.

That is the amount of time a patient was kept alive by the SynCardia Total Artificial Heart while waiting for a donor transplant, Picard Medical Inc. announced.

The 29-year-old patient (not identified) received the SynCardia Total Artificial Heart on Sept. 2, 2021, after developing severe biventricular heart failure. The device replaced the pumping function of both sides of the heart, maintaining circulation while the patient awaited a donor organ. After 1,636 days of continuous artificial heart support, the patient underwent a successful heart transplant on Feb. 24, 2026.

“The challenge in advanced heart failure is often the time required to find a suitable donor organ,” Picard Medical CEO Patrick N.J. Schnegelsberg stated. “This case demonstrates how the SynCardia Total Artificial Heart can sustain critically ill patients for extended periods, allowing them to live at home while awaiting heart transplantation.”

Total artificial heart therapy is indicated as a bridge to transplant for patients with irreversible biventricular heart failure who cannot be supported with isolated left ventricular assist device therapy. By replacing both ventricles and all four native heart valves, the SynCardia Total Artificial Heart restores circulation and hemodynamic stability while patients await donor organ availability.

More than 2,100 SynCardia Total Artificial Heart implants have been performed worldwide in patients with advanced biventricular heart failure, with the longest documented patient support exceeding eight years on device, officials said.

While individual outcomes may vary, extended duration support cases continue to inform clinical practice and illustrate the potential for long term mechanical circulatory support in carefully selected patients, according to the company.

Picard Medical Inc. is the parent company of SynCardia Systems LLC, a Tucson, Ariz.–based provider of the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart, the first such device approved by both the U.S. Food and Drug Administration and Health Canada. With more than 2,100 implants performed at hospitals across 27 countries, SynCardia’s device reportedly is the world’s most widely used and extensively studied artificial heart.